LAWRENCE, Mass., May 10, 2017 /PRNewswire/ -- NxStage
Medical, Inc. (NASDAQ: NXTM), a leading medical technology company
focused on advancing renal care, today announced that its next
generation hemodialysis system has received FDA clearance.
This innovative system consists of new features and capabilities,
including a new touchscreen user interface and integrated blood
pressure monitor designed to enhance ease of use for patients
performing home hemodialysis.
"Early customer and patient feedback in the UK on our next
generation system has been very positive, validating many of the
benefits we expected," said Joseph E.
Turk, president of NxStage Medical, Inc. "We are very
excited to bring these new features and capabilities that are
designed to significantly improve our patients' therapy experience
to the US market. The touch screen interface provides an excellent
platform to continue bringing new features and functionality moving
forward."
About the NxStage System One
The NxStage System One is the first and only truly portable
hemodialysis system cleared specifically by the FDA for
home hemodialysis and home nocturnal hemodialysis. The simplicity
and revolutionary size (just over a foot tall) are intended to
allow convenient use in patients' homes and give patients the
freedom to travel with their therapy. When combined with the
NxStage PureFlow™ SL Dialysis Preparation System, patients are able
to further simplify, using ordinary tap water to create dialysis
fluid on-site on-demand. Unlike conventional hemodialysis systems,
the System One family of products requires no special
infrastructure to operate. Under the guidance of their physician,
patients can use the NxStage System One, with their trained
partners, where, how and when it best meets their needs, including
while they are sleeping - at home or on vacation and at a medically
appropriate treatment frequency. In addition, NxStage's Nx2me
Connected Health® platform collects important NxStage System One
and patient information for flexible viewing, monitoring and
reporting that may improve patient management and patient
retention, as well as simplify alternative site care. The System
One is also used to provide a range of flexible therapy options in
more traditional care settings such as hospitals and dialysis
centers. Its safety and performance have been demonstrated by
experience with more than 14 million treatments with over 30
thousand patients around the
world. http://www.nxstage.com/.
About NxStage
NxStage Medical, Inc. (Nasdaq: NXTM) is a leading medical
technology company, headquartered in Lawrence, Massachusetts, USA, that develops,
manufactures and markets innovative products for the treatment of
end-stage renal disease (ESRD) and acute kidney failure. NxStage
has also established a small number of dialysis clinics committed
to the development of innovative care delivery models for patients
with ESRD. For more information on NxStage and its products and
services, please visit the Company's website
at http://www.nxstage.com and www.nxstagekidneycare.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements contained in this release that are not clearly
historical in nature are forward-looking, and the words
"anticipate," "believe," "expect," "estimate," "plan," and similar
expressions are generally intended to identify forward-looking
statements. Actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors including those that are discussed in
NxStage's filings with the Securities and Exchange Commission,
including its Quarterly Report on Form 10-Q for the quarter ended
March 31, 2017. NxStage is under no
obligation to (and expressly disclaims any such obligation to)
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
Contact:
Kristen K.
Sheppard, Esq.
VP, Investor Relations
ksheppard@nxstage.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nxstage-medical-announces-fda-clearance-for-its-new-system-one-hemodialysis-system-300455345.html
SOURCE NxStage Medical, Inc.